10-Q: Tenon Medical Reports Improved Gross Profit Despite Ongoing Losses in Q2 2024

Tenon Medical's Q2 2024 results show increased revenue and gross profit, but the company continues to operate at a loss and faces going concern uncertainty.

Summary

• Tenon Medical reported a net loss of $3.8 million for the three months ended June 30, 2024, and a net loss of $7.4 million for the six months ended June 30, 2024.
• Revenue increased to $901,000 for the quarter and $1.62 million for the six-month period, driven by a rise in surgical procedures using the Catamaran System.
• Gross profit improved significantly to $470,000 for the quarter and $940,000 for the six-month period, with gross margin percentages increasing to 52% and 58% respectively.
• Operating expenses totaled $4.3 million for the quarter and $8.3 million for the six-month period, with decreases in research and development and sales and marketing expenses offset by increases in general and administrative costs.
• The company's accumulated deficit reached $62.5 million as of June 30, 2024.
• Tenon Medical has substantial doubt about its ability to continue as a going concern for the next twelve months and plans to raise additional capital through various means.

Sentiment

Score: 3

Explanation: The document highlights some positive trends in revenue and gross profit, but the significant net losses, going concern uncertainty, and ineffective disclosure controls create a negative overall sentiment. The need for additional capital raises further underscores the financial challenges.

Positives

• Revenue increased due to a higher number of surgical procedures using the Catamaran System.
• Gross profit and gross margin percentages improved significantly due to better absorption of production overhead costs and operating leverage.
• The company successfully raised $2.6 million through a private placement of Series A Preferred Stock.
• Operating expenses decreased in research and development and sales and marketing.

Negatives

• The company continues to operate at a net loss, with a $3.8 million loss for the quarter and a $7.4 million loss for the six-month period.
• There is substantial doubt about the company's ability to continue as a going concern for the next twelve months.
• The company's disclosure controls and procedures are not effective at the reasonable assurance level due to a lack of segregation of duties.
• The company received a notice from Nasdaq for not maintaining the minimum bid price of $1.00 per share.

Risks

• The company's ability to continue as a going concern is uncertain due to ongoing losses and negative cash flows.
• The company may not be able to raise sufficient additional capital through public or private equity offerings, debt financings, or collaborations.
• Failure to regain compliance with Nasdaq's minimum bid price rule could lead to delisting.
• The company's disclosure controls and procedures are not effective, which could lead to inaccurate financial reporting.
• The company faces risks related to competition, technology changes, and intellectual property protection.

Future Outlook

The company plans to raise additional capital through public or private equity offerings, debt financings, and collaborations to fund its operations and working capital requirements. The company expects to incur additional losses in the future.

Management Comments

• Management believes that the implant design and procedure they have developed will be well received by the clinician community.
• Management expects operating expenses to increase as they continue to invest and grow the business.
• Management believes that the company's existing cash and cash equivalents will not be sufficient to fund operating expenses and working capital requirements for the next 12 months.

Industry Context

The company operates in the competitive medical device industry, specifically in the market for sacroiliac joint fusion systems. The company is focused on commercializing its Catamaran System and addressing the underserved market for SI joint disorders. The company's results are impacted by factors such as reimbursement, changes in sales representatives, and physician activities, which are common in the orthopedic industry.

Comparison to Industry Standards

• Tenon Medical's gross margin improvement to 58% for the six months ended June 30, 2024, is a positive sign, but it is still below the industry average for established medical device companies, which often have gross margins above 70%.
• Companies like Medtronic and Stryker, which are leaders in the orthopedic space, have significantly higher revenue and profitability due to their established market presence and diverse product portfolios.
• Smaller companies in the medical device sector often face challenges in achieving profitability due to high research and development costs and the need for extensive sales and marketing efforts.
• Tenon's reliance on a single product, the Catamaran System, makes it more vulnerable to market fluctuations and competition compared to companies with a broader range of products.
• The company's need to raise additional capital is a common challenge for early-stage medical device companies, as they often require significant investment to achieve commercial success.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders face the risk of dilution from potential capital raises and the possibility of delisting from Nasdaq.
• Employees may be impacted by potential cost-cutting measures if the company is unable to secure additional funding.
• Customers (clinicians) may be concerned about the company's long-term viability and its ability to support the Catamaran System.
• Suppliers and creditors face increased risk due to the company's financial instability.

Next Steps

• The company will evaluate options to regain compliance with Nasdaq's minimum bid price rule.
• The company will seek to raise additional capital through various means.
• The company will continue to focus on commercializing the Catamaran System and expanding its sales and marketing efforts.

Key Dates

Keywords

medical devices, sacroiliac joint fusion, Catamaran System, spinal implants, financial results, going concern, reverse stock split, Series A Preferred Stock, Nasdaq compliance, surgical procedures